UroGen Pharma Ltd. Additional Paid in Capital
UroGen Pharma Ltd. (URGN) had Additional Paid in Capital of $399.60 million as of 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Balance Sheet
us-gaap:AdditionalPaidInCapital · last filed 2019-11-12
- 2019-09-30: Additional Paid in Capital $399.60M.
- 2019-06-30: Additional Paid in Capital $391.23M.
- 2019-03-31: Additional Paid in Capital $383.85M.
- 2018-12-31: Additional Paid in Capital $212.92M.
| Period end | Additional Paid in Capital |
|---|---|
| 2019-09-30 | $399.60M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $391.23M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $383.85M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $212.92M 10-Q · filed 2019-11-12 |
| 2018-09-30 | $202.69M 6-K · filed 2018-11-13 |
| 2018-06-30 | $192.13M 6-K · filed 2018-08-14 |
| 2018-03-31 | $184.42M 6-K · filed 2018-05-15 |
| 2017-12-31 | $115.69M 10-K · filed 2019-02-28 |
| 2016-12-31 | $43.50M 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |